Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Faron Pharmaceuticals Ltd on Friday reported a widened loss in 2022 as it ramped up its research & development efforts.
The Turku, Finland-based biopharmaceutical drug discovery and development company said pretax loss widened 36% to €28.7 million in 2022 from €21.2 million a year prior. Faron Pharma does not yet generate revenue.
Research & development expenses increased 19% to €20.7 million from €17.4 million. Meanwhile, general & administrative expenses narrowed 25% to €7.5 million from €9.9 million, despite raising its headcount to 40 employees at the end of 2022 from 37 a year before. The company incurred a financial expense of €1.4 million in 2022, up sharply from €235,000 in 2021.
Faron Pharmaceuticals said one of its 2022 highlights was the successful conduction of two fundraising rounds, raising €13.4 million gross in total via new and existing investors.
Further, it obtained up to €30 million in debt funding from IPF Partners, and drew €10.0 million upon signing in February 2022. IPF Partners is a Luxembourg-based investor in emerging commercial stage pharmaceutical companies, among others.
Faron said another highlight was that ‘Bexmarilimab has been evaluated as a single agent in the Phase I/II MATINS in more than 200 patients and found to be well-tolerated’.
Bexmarilimab is the company’s wholly-owned precision immunotherapy, in combination with standard of care in aggressive hematological malignancies including acute myeloid leukemia and myelodysplastic syndrome.
Chief Executive Officer Markku Jalkanen said: ‘Last year we accelerated the development of bexmarilimab in hematological malignancies and reported exciting early data that lays a solid trajectory. We also demonstrated compelling antitumor activity in heavily pretreated patients across multiple solid tumor types, setting the stage for a combination with standard of care in first-line solid tumors.’
Faron Pharmaceuticals shares were 3.0% lower at 320.15 pence each in London on Friday morning.
Copyright 2023 Alliance News Ltd. All Rights Reserved.